|
Ophthalmic Pharmaceutical Drugs
|
| Global Industry Analyst | 488 pages | Janvier 2007 | Anglais
| |
This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ Million.
The major therapeutic categories analyzed are Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inf ... |
3.160,00 € |
| |
| |
|
|
| |
|
|
Emerging Pharmaceutical Markets Globally
|
| RNCOS | 250 pages | Janvier 2008 | Anglais
| |
| The report ``Emerging Pharmaceutical Markets Globally`` provides an exhaustive overview of the pharmaceutical markets in the E7 countries (Brazil, Russia, India, China, Mexico, Turkey and Indonesia). ... |
1.440,00 € |
| |
| |
|
|
| |
|
|
Endo Pharmaceuticals Holdings Inc. - SWOT Analysis
|
| Datamonitor | 28 pages | Mars 2008 | Anglais
| |
Datamonitor's Endo Pharmaceuticals Holdings Inc.
- SWOT Analysis Company Profile is the essential source for top-level company data and information.
The report examines the company’s key busines ... |
100,00 € |
| |
| |
|
|
| |
|
|
Eastern Europe Panorama Pharmaceuticals 2004
|
| Snapshots International | 17 pages | Décembre 2004 | Anglais
| |
Snapdata's Eastern Europe Panorama Pharmaceuticals 2004 report provides 2003 year-end market data, with 2004 estimates and five-year forecasts.
The report gives an instant overview of the Eastern E ... |
850,00 € |
| |
| |
|
|
| |
|
|
A Guide to Drug Pricing and Reimbursement
|
| Kalorama Information | 200 pages | Septembre 2007 | Anglais
| |
Drug pricing is one of the key levers that determine the profitability of a drug company.
Premium pricing of a new drug helps cover the high cost of innovation and helps run a profitable enterprise ... |
1.596,00 € |
| |
| |
|
|
| |
|
|
|
|
Santarus, Inc. - SWOT Analysis
|
| Datamonitor | 20 pages | Juillet 2007 | Anglais
| |
Datamonitor's Santarus, Inc.
- SWOT Analysis Company Profile is the essential source for top-level company data and information.
The report examines the company’s key business structure and oper ... |
100,00 € |
| |
| |
|
|
| |
|
|
The Generics Outlook 2001
|
| Business Insight | 242 pages | Février 2001 | Anglais
| |
“By the year 2004, it is expected that the value of the total western European generics sector may have risen to $19 billion, representing almost 15% of allpharmaceuticals.
In the USA, the val ... |
955,00 € |
| |
| |
|
|
| |
|
|
|
|
|
